Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2025-12-24 @ 7:51 PM
NCT ID:
NCT02113904
Eligibility Criteria:
Inclusion Criteria:
* Patient over 4 years of age at the time of enrolment
* Patient with a clinical, immuno-histochemical and/or molecular diagnosis confirmed
* Vaccinations to date
* Informed consent form signed by the patient and/or his parents (or the legal authority) if the patient is a child
* Patient with social security coverage
Exclusion Criteria:
* Ongoing severe infections
* Well known allergy to one of Adalimumab ingredients
* Allergy to xylocaine
* Ongoing treatment to immunosuppressive drugs and biotherapies
* History of malignancy
* Heart, renal, haematological and/or confirmed hepatic involvement
* Pregnant, or breastfeeding, patients
* Anomalies of the standard balance sheet: neutropenia \< 1000/mm3, polynucleose \> 12 000 / mm3 - lymphopenia \< 1000 / mm3 - anemia \< 9g / 100ml - thrombocytopenia \< 150 000 /mm3, thrombocytosis \> 500 000/mm3 - transaminase \> 3N
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
4 Years
Study:
NCT02113904
Study Brief:
Protocol Section:
NCT02113904